Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients

Ocular Hypertension Clinical Trial

Official title:

Efficacy and Safety Assessment of Fixed Combination Unpreserved Latanoprost Eye Drops and Timolol 0.5% (T2347) Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02278614
• Other study ID #: LT2347-PIII-12/13
• Status: Completed
• Phase: Phase 3
• First received: October 15, 2014
• Last updated: March 16, 2016
• Start date: December 2014
• Est. completion date: November 2015

Study information

• Verified date: February 2016
• Source: Laboratoires Thea
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santéSpain: Agencia Espanola de Medicamentos y Productos SanitariosGermany: Federal Institute for Drugs and Medical DevicesUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyBelgium:Federal Agency for Medecines and Health ProductsRussia: Ministry of Health of the Russian FederationPoland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsHungary:Ministry of Health of HungaryEstonia: Ministry of Health of EstoniaLatvia: Ministry of health of Latvia
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to assess the efficacy and safety of T2347 (Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops) versus Xalacom® in ocular hypertensive or glaucomatous patients initially treated, stabilised by Xalacom® or generics (fixed combination Latanoprost 0.005% + Timolol 0.5% preserved eye drops).

Description:

Phase III, international, multicentre, randomised, investigator masked, 3 month duration, 2 parallel groups, 2 X 97 evaluable patients

Recruitment information / eligibility

• Status: Completed
• Enrollment: 242
• Est. completion date: November 2015
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed and dated informed consent,

• Male or female aged > 18 years old,

• Both eyes with open angle glaucoma or ocular hypertension already treated and controlled by Xalacom® or generics (fixed combination Latanoprost 0.005% + Timolol 0.5% preserved eye drops) since at least 2 months.

• IOP = 18 mmHg in both eyes

• History of IOP insufficiently controlled with first-line monotherapy based on the investigator judgement (e.g. non reaching the target IOP)

• History of an add-on IOP reduction with Xalacom® or generics (fixed combination Latanoprost 0.005% + Timolol 0.5% preserved eye drops) in comparison with first-line treatment

• Corneal thickness = 500 µm and = 600 µm in both eyes.

Exclusion Criteria:

• Ophthalmic exclusion criteria (in either eye)

• Fundoscopy, VF not performed or not available within the 6 months before inclusion visit.

• Significant worsening according to the two last VF (minimum 6 months between these 2 VF)

• Advanced stage of glaucoma:

• Best far corrected visual acuity = 1/10.

• History of trauma, infection, clinically significant inflammation within the 3 months before inclusion visit.

• Ongoing or known history of ocular seasonal and perennial allergy (SAC, PAC) and/or uveitis and/or viral infection.

• Presence of at least one severe objective sign among the following:

• Hyperaemia (Grade 5)

• Superficial punctate keratitis (Grade 3)

• Blepharitis (Grade 3)

• Severe dry eye (defined by severe epithelial erosions of the cornea and/or use of dry eye medication with a frequency exceeding 8 instillations / day).

• Corneal ulceration.

• Palpebral abnormalities not related to medical treatment study and incompatible with a good evaluation.

• History of corneal refractive surgery.

• Any abnormality preventing accurate assessment e.g. reliable tonometry measurement, visual field examination.

Systemic/non ophthalmic exclusion criteria

• Non-controlled diabetic patient.

• Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease.

• Sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker, overt cardiac failure, cardiogenic shock.

• Heart rate <50 bpm, systolic arterial blood pressure= 90 mm Hg

• Known or suspected hypersensitivity to one of the components of the study product.

• Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease: hepatic, endocrine, neoplastic, haematological; immunosuppressive, infectious diseases, severe psychiatric illness, relevant cardiovascular abnormalities, etc… and/or any complicating factor or structural abnormality, judged by the investigator to be incompatible with the study.

Specific exclusion criteria for women

• Pregnancy, lactation.

• Childbearing potential woman who is not using a reliable method of contraception

Exclusion criteria related to general conditions

• Inability of patient to understand the study procedures and thus inability to give informed consent.

• Non-compliant patient

• Participation in another clinical study with investigational drug within the last 3 months.

• Already included once in this study.

• Patients being institutionalised because of legal or regulatory order, inmates of psychiatric wards, prison or state institutions, and employees of the study sites or of the Sponsor's company.

• Ward of court.

• Patient not covered by government health care scheme in the country (if applicable).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glaucoma, Open-Angle
• Ocular Hypertension
• Open Angle Glaucoma

Intervention

Drug:
• T2347
T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
• Xalacom
Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.

Locations

Country	Name	City	State
France	Laboratoires Thea	Clermont ferrand

Sponsors (1)

Lead Sponsor	Collaborator
Laboratoires Thea

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	non-inferiority of T2347 compared with Xalacom® on change in mean IOP at 9.00 am (± 1 hour) between the baseline (Day 0) and Day 84 in the worse eye	the non-inferiority of T2347 unpreserved eye drops compared with Xalacom® on change in mean IOP at 9.00 am (± 1 hour) between the baseline (Day 0) and Day 84 in the worse eye	Day 84	No